PHOTOCURE TO PRESENT DATA ON IMPACT OF HEXVIX®/CYSVIEW® ON LONG TERM RECURRENCE RATES AT AMERICAN UROLOGICAL ASSOCIATION ANNUAL MEETING, ATLANTA, USA
Full data published in Journal of Urology
Oslo, Norway, May 22 2012: Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announced today that data will be presented on its flagship product to aid in diagnosing bladder cancer, Hexvix/Cysview, at the American Urological Association (AUA) Annual Meeting in Atlanta, USA on Tuesday 22 May 2012.
The data on Hexvix/Cysview, from a long term follow-up study in 551 patients, indicates that Hexvix cystoscopy significantly improves time to recurrence of bladder cancer. Professor H. Barton Grossman, (Houston, TX) will be presenting this data on Tuesday 22 May at 11:00 am.
H. Barton Grossman, Clinical Professor, MD Anderson Cancer Center, commented: "Hexvix/Cysview is a significant advance in detecting and treating bladder cancer. These data demonstrate that the recurrence of bladder cancer is reduced and importantly show a trend towards improved bladder preservation, which is of huge importance to patients and their quality of life."
Kjetil Hestdal, President and Chief Executive Officer of Photocure, commented: "These positive long term follow-up data presented today at this prestigious conference are testament to the effectiveness of Hexvix in detecting bladder cancer. We are further encouraged by the positive response from urologists following the launch of Cysview in the US."
The data has been published in the online edition of the peer-reviewed Journal of Urology and can be found at the following link: http://www.jurology.com/article/S0022-5347(12)01888-5/fulltext
Hexvix/Cysview is the first approved drug-device combination procedure for improved detection of bladder cancer. It is designed to induce fluorescence in the malignant cells in the bladder during a cystoscopic procedure, making it easier for the urologist to detect non muscle invasive bladder cancer, as an adjunct to white light cystoscopy. It is the first product in a new diagnostic class known as Photodynamic Diagnostic (PDD) agents. Hexvix/Cysview is an approved product in Europe and the US. Photocure markets and sells Hexvix in the Nordic region, and has initiated the commercialization of Cysview directly in the US. Ipsen is commercializing Hexvix in the rest of the world.
For further information, please contact:
Photocure
President & CEO Kjetil Hestdal
Tel: + 47 913 19 535, Email: kh@photocure.no
M: Communications
Mary Clark, Amber Bielecka, Hollie Vile
Tel: +44 207920 2361, Email: photocure@mcomgroup.com
About Photocure ASA
Photocure ASA is a worldwide leader in photodynamic technology. Listed on the Oslo Stock Exchange (OSE: PHO), Photocure is focused on photodynamic technologies in dermatology and cancer. The company strives to solve unmet needs by developing new and innovative solutions based on its patented Photocure Technology(TM). Photocure markets and sells its own products in selected markets and has developed strong partnerships with leading pharmaceutical companies on a regional and global basis. Photocure's bladder cancer diagnostic product, Cysview/Hexvix is approved in Europe and the US. In addition, the company markets Allumera®, a photodynamic cosmetic in the US. Setting new standards for diagnosis and treatment of several different conditions, Photocure Technology(TM) is continuously being tested for new products and applications in cancer and dermatology.
Visonac®, Allumera®, Photocure® and Cysview®/Hexvix® are registered trademarks of Photocure ASA. For more information about Photocure, visit www.photocure.com.